首頁 › 瀰漫性大B細胞淋巴瘤 › 德克薩斯州 › Houston
Houston, TX 的 瀰漫性大B細胞淋巴瘤 臨床試驗
17 項針對 瀰漫性大B細胞淋巴瘤 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中觀察性研究
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
招募中1 期
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
其他城市的 瀰漫性大B細胞淋巴瘤 試驗
- New York City, NY21 項研究
- Baldwin Park, CA19 項研究
- Chicago, IL18 項研究
- Los Angeles, CA17 項研究
- Boston, MA16 項研究
- Milwaukee, WI16 項研究
- Nashville, TN15 項研究
- Portland, OR15 項研究
- Philadelphia, PA15 項研究
- Durham, NC14 項研究
- Dallas, TX13 項研究
- Seattle, WA12 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。